Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,477 total articles
TXO Partners (TXO) offers a favorable risk-reward into Q2 earnings: strong free cash flow, an attractive distribution ($0.36 quarterly), reasonable leverage, and constructive technicals. Enter around $13.10 with a $12.20 stop and a primary target at $15.50 (52-week high) over a mid-term (45 trading days) horizon.
Seagate ($STX) still benefits from AI-driven data-center storage demand, but the stock carries a premium — P/E roughly 71x and P/FCF ~85x — that leaves the market little tolerance for disappointing guidance. This trade idea outlines an actionable long entry on weakness ahead of earnings with a defined stop and target across a 180 trading-day horizo…
Himax Technologies has pulled roughly half off its June highs. Fundamentals show product traction in OLED touch ICs, LCoS microdisplays for AR, and growing edge-AI capabilities, while the valuation and technicals suggest a tactical long-swing opportunity. This trade targets a recovery toward the mid-$teens as mean reversion meets upcoming catalysts…
Capital One's Q2 performance confirms improving credit trends and a profitable capital base while the Discover migration (starting 07/27/2026) and targeted $2.7B of synergies support a re-rating. The stock trades at roughly mid-40s P/E and near book value, leaving upside if delivery on integration and continued credit discipline persist. Trade idea…
A favorable regulatory development on therapeutic peptides, paired with management's operational adjustments and resilient revenue guidance, justify upgrading Hims & Hers to a Buy. Short interest and convertible debt remain tangible risks, but the setup offers asymmetric upside for disciplined, sized positions over the next 180 trading days.
Tarsus has turned a clear commercial engine with XDEMVY, delivering $451.4M in 2025 net product sales and a strongly profitable gross margin profile. Q1 2026 net product sales topped $145M (up ~85% YoY) and management reaffirmed full-year guidance of $670-700M. With a market cap of roughly $2.5B and $709M of cash on the balance sheet, the equity lo…
Charter Communications is trading at multi-year distressed multiples despite positive free cash flow, low P/E and attractive EV/EBITDA. This is a tactical long trade: enter $119.19, stop $98.00, target $170.00 with a long-term (180 trading days) horizon. The risk/reward favors buyers who accept industry headwinds and near-term headline volatility.
Micron looks attractively positioned after the pullback. Strong AI/data-center demand, impressive profitability metrics, and a conservative balance sheet make a long entry compelling. Trade plan anchored to product-led revenue upside from the Kimi K3 ramp, with clear stops and a 180-trading-day horizon.
Ladder Capital (LADR) trades under $10 with a near 9% yield and improving dividend coverage supported by roughly $100M in free cash flow. This trade idea buys the rebound toward prior resistance while protecting against downside through a tight stop. The thesis rests on steady distributable earnings, sub-1.0 price-to-book and a market cap of about …
SpaceX's optionality from Starlink recurring revenue, Starship scale economics, and a predictable government revenue base is being discounted. I upgrade to a buy and lay out an actionable entry, target and stop for a long trade that expects re-rating over the next 180 trading days.
Otis is a high-quality, service-heavy industrial franchise showing steady cash generation and a shareholder-friendly dividend. Near-term technicals and industry headwinds constrain immediate upside, but the company's scale in service and steady free cash flow support a constructive mid-term trade and a longer-term bullish view.
Visa looks set to deliver another reliable quarter driven by resilient payments volumes, cross-border recovery and robust cash generation. Valuation is full but not extreme for a dominant, high-margin franchise. This trade idea lays out a short-term (10 trading days) long with an entry at $354.00, stop at $344.00 and a $370 target.
Dave Inc. has become a profitable, high-margin fintech but its valuation and recent technical setup leave it exposed to a downside re-rating. For investors who want banking exposure without payday-like credit economics, owning coastal, BaaS-style franchises is the cleaner trade. We lay out an actionable short on DAVE with entry, stop and target, pl…
Brookfield Infrastructure (BIP) is a high-quality infrastructure owner with inflation-linked cash flows and a healthy distribution. The company announced a plan to simplify into a single public corporation, and that corporate action plus upcoming Q2 results create a clear catalyst window. This trade idea outlines a long entry with precise entry, st…
AbbVie offers a durable dividend backed by strong free cash flow and a diversified drug portfolio. At $258.38 the stock trades like a mature pharma with growth optionality from immunology and oncology assets. This trade idea lays out an entry at $258.38, stop at $235.00 and a 180-day target of $300.00, with concrete catalysts and downside scenarios…
RTX is trading up on a clear beat-and-raise storyline: robust backlog, defensive tailwinds from rising defense budgets, and healthy free cash flow. Valuation is rich but not irrational given scale and cash generation. This trade targets a mid-term upside while protecting capital with a defined stop.
Stride has stabilized execution after last year’s platform troubles, reinforced guidance and lifted adjusted op income expectations, and today trades at roughly $3.66B market cap and single-digit EV/EBITDA multiples. This trade idea lays out an actionable long with entry, stop and target and explains why a revisit to prior multiples makes a 50%+ up…
Skyworks (SWKS) has retreated from last year's highs and is now trading around $60.40, offering a chance to accumulate ahead of Q3 results, product ramps in EV traction inverters, and continued progress on the Qorvo merger. Strong free cash flow ($703.6M last reported), a healthy balance sheet (cash $1.07B; debt-to-equity 0.17), and a ~4.7% dividen…
Shinhan Financial (SHG) looks like a practical, event-driven long: an earnings beat has reset expectations, management has room to increase shareholder returns, and valuation is inexpensive with a market cap of roughly $34.0B, a PE near 10 and PB below 1. This trade targets a move toward a new premium on the back of capital allocation and continued…
Veeva delivered another quarter of steady growth and raised FY2027 guidance. At roughly $184, the stock offers exposure to a high‑quality life‑sciences SaaS franchise trading at a reasonable multiple relative to its cash flow and profitability. We lay out a mid‑term (45 trading days) long with clear entry, stop, and target, plus the catalysts and r…
Bloom Energy has been the market's go-to name for on-site power for AI data centers. A sharp pullback from June highs has created a window to buy a leader with meaningful contracts (Oracle, Brookfield), positive free cash flow, and a market cap under $60B. This is an actionable, high-risk long trade with clearly defined entry, stop and target tied …
Amazon is trading near $232 as the market frets about an accelerating AI capex cycle. The company's negative free cash flow and rising spending are real, but so is the payoff: stronger AWS customer lock-in, higher long-term margins and faster revenue growth. This trade idea buys the dip with a 180-trading-day horizon, a strict stop and a target nea…
Amazon trades near $232 with a $2.5T market cap after a pullback driven by headline risk around competitor capex and an upcoming Q2 print on 07/30/2026. Fundamentals - led by AWS and advertising - remain intact, valuation is not exuberant (EV/EBITDA ~16.2, P/E ~28-30), and technicals show room to recover (RSI ~38). This trade idea recommends a long…
Legend Biotech ($LEGN) has been beaten down from last year's highs, but recent Phase 1 data for an in vivo CD19/CD20 CAR-T and a $226M public offering give a constructive setup. I think the risk/reward favors a long at current levels, provided you use a disciplined stop and a mid-to-long-term horizon tied to upcoming clinical readouts and commercia…
Broadcom pulled back sharply in the recent AI-led selloff, leaving a high-quality cash-flow machine trading well below its June peak. Fundamentals remain intact - double-digit ROE, $32.8B in free cash flow and a $1.9T enterprise value - while short-term technicals and macro headlines create a tactical opportunity. This trade idea outlines a precise…
